Guidelines for the management of osteoporosis induced by endogenous hypercortisolism are not available. Both the American College of Rheumatology and the International Osteoporosis Foundation recommend to modulate the treatment of exogenous glucocorticoid-induced osteoporosis (GIO) based on the individual fracture risk profile (calculated by FRAX) and dose of glucocorticoid used, but it is difficult to translate corticosteroid dosages to different degrees of endogenous hypercortisolism, and there are no data on validation of FRAX stratification method in patients with endogenous hypercortisolism. Consequently, it is unclear whether such recommendations may be adapted to patients with endogenous hypercortisolism. Moreover, patients with exogenous GIO take glucocorticoids since suffering a disease that commonly affects bone. On the other hand, the correction of coexistent risk factors, which may contribute to increase the fracture risk in patients exposed to glucocorticoid excess, and the removal of the cause of endogenous hypercortisolism, may lead to the recovery of bone health. Although the correction of hypercortisolism and of possible coexistent risk factors is necessary to favor the normalization of bone turnover with recovery of bone mass; in some patients, the fracture risk could not be normalized and specific anti-osteoporotic drugs should be given. Who, when, and how the patient with endogenous hypercortisolism should be treated with bone-active therapy is discussed.
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? / Scillitani, A.; Mazziotti, G.; Di Somma, C.; Moretti, S.; Stigliano, Antonio; Pivonello, R.; Giustina, A.; Colao, A.; Abc Group Collaborators: Albiger, N.; Ambrogio, A.; Arnaldi, G.; Arvat, E.; Roberto, Baldelli; Berardelli, R.; Boscaro, M.; Cannavò, S.; Cavagnini, F.; Colao, A.; Corsello, S. m.; Cozzolino, A.; De Bartolomeis, A.; De Leo, M.; Di Minno, G.; Di Somma, C.; Esposito, K.; Fabbrocini, G.; Ferone, D.; Foresta, C.; Galderisi, M.; Giordano, C.; Giugliano, D.; Giustina, A.; Grimaldi, F.; Isidori, Andrea; Jannini, Emmanuele A.; Lombardo, Francesco; Manetti, L.; Mannelli, M.; Mantero, F.; Marone, G.; Mazziotti, G.; Moretti, S.; Nazzari, E.; Paragliola, R. m.; Pasquali, R.; Pecorelli, S.; Pecori Giraldi, F.; Pivonello, C.; Pivonello, R.; Reimondo, G.; Scaroni, C.; Scillitani, A.; Simeoli, C.; Toscano, V.; Trementino, L.; Vitale, G.; Zatelli, M. c.. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 25:2(2014), pp. 441-446. [10.1007/s00198-013-2588-y]
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?
A. Scillitani;STIGLIANO, Antonio;A. Cozzolino;ISIDORI, Andrea;LOMBARDO, Francesco;
2014
Abstract
Guidelines for the management of osteoporosis induced by endogenous hypercortisolism are not available. Both the American College of Rheumatology and the International Osteoporosis Foundation recommend to modulate the treatment of exogenous glucocorticoid-induced osteoporosis (GIO) based on the individual fracture risk profile (calculated by FRAX) and dose of glucocorticoid used, but it is difficult to translate corticosteroid dosages to different degrees of endogenous hypercortisolism, and there are no data on validation of FRAX stratification method in patients with endogenous hypercortisolism. Consequently, it is unclear whether such recommendations may be adapted to patients with endogenous hypercortisolism. Moreover, patients with exogenous GIO take glucocorticoids since suffering a disease that commonly affects bone. On the other hand, the correction of coexistent risk factors, which may contribute to increase the fracture risk in patients exposed to glucocorticoid excess, and the removal of the cause of endogenous hypercortisolism, may lead to the recovery of bone health. Although the correction of hypercortisolism and of possible coexistent risk factors is necessary to favor the normalization of bone turnover with recovery of bone mass; in some patients, the fracture risk could not be normalized and specific anti-osteoporotic drugs should be given. Who, when, and how the patient with endogenous hypercortisolism should be treated with bone-active therapy is discussed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
